Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology

Camisa, C.

doi:10.1001/archderm.125.3.407

Cited by 10 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest a 5-20-fold increase in IGF-I receptor kinase activity in lesional psoriatic epidermis compared with uninvolved skin from the same individuals. A role for participation of the IGF-I receptor-ligand system in the pathogenesis of psoriasis is further suggested from clinical improvement produced by somatostatin-like drugs that diminish plasma IGF-I concentrations (31). Furthermore, activation of the increased IGF-I receptors present in lesional psoriatic skin might increase EGF receptor expression (a characteristic of psoriatic epidermis) via IGF-I-mediated transmodulation of the EGF receptor (9).…”

Section: Discussionmentioning

confidence: 99%

The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor.

Krane

Gottlieb

Carter

et al. 1992

The Journal of Experimental Medicine

View full text Add to dashboard Cite

SummaryInsulin-like growth factor I (IGF-I)/somatomedin C is an important mediator of keratinocyte growth in vitro, and the expression of IGF-I receptors in the basal layer of normal epidermis suggests that this growth pathway may function in the regulation of keratinocyte growth in vivo as well. The pattern of IGF-I receptor expression in normal skin is distinct from that of the epidermal growth factor (EGF) receptor, suggesting that these receptors might be differentially regulated. The purpose of this study was to obtain a better understanding of IGF-I receptor function in the skin by examining IGF-I receptor expression in psoriatic epidermis and in cultured human keratinocytes. Our findings indicate that IGF-I receptor expression is increased in psoriasis as measured by protein tyrosine kinase assays of biopsy extracts and by immunohistochemical staining with an IGF-I receptor-specific monoclonal antibody. Unlike EGF receptor expression, which is also increased in psoriatic epidermis, the pattern of IGF-I receptor expression corresponds closely with the increased size of the keratinocyte proliferative compartment in psoriasis. Biochemical agents that diminish EGF receptor ligand binding (phorbol ester or calcium ionophore treatment) produce opposite effects on the IGF-I receptor. These results suggest that cellular expression and differential regulation of both growth factor receptor systems may control critical aspects of epidermal proliferation or function.

show abstract

Section: Discussionmentioning

confidence: 99%

The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor.

Krane

Gottlieb

Carter

et al. 1992

The Journal of Experimental Medicine

View full text Add to dashboard Cite

show abstract

“…Weber et al [1] have observed elevated levels of GH in 70 psoriatic patients; somatostatin therapy was responsible for improvement or disappearance of the skin lesions in 22 out of 26 patients [2], Similar therapeutic results have been obtained by others [3][4][5]. However, other reports failed [6] or could not correlate raised plasma GH levels to demonstrate any variation in promoting psoriasis |7].…”

Section: Introductionmentioning

confidence: 76%

“…The role of GH in psoriasis was first raised by Weber et al [1|, who found increased plasma GH levels in 70 patients with psoriasis of all clinical forms. Moreover, GH levels were significantly higher in patients with extensive psoriasis; GH inhibitors (bromocriptin and somatostatin) were responsible for the clear ing of skin lesions [2][3][4][5]. Recently, Weber and Heitz [12] reported hyperplasia of GH-producing cells in the pitui tary glands of 12 postmortem patients with psoriasis, although there is no tendency to develop psoriasis in con ditions of inappropriate GH secretion as in acromegalic patients.…”

Section: Discussionmentioning

confidence: 99%

Relapsing Eruptive Psoriasis and Immunological Changes Triggered by Growth Hormone Therapy in a Growth Hormone-Deficient Girl

et al. 1990

View full text Add to dashboard Cite

show abstract

“…In addition, it slows down a number of pathological mechanisms, in particular inflammatory and granulomatous reactions. In the field of dermatology, somatostatin treatment has been used to control psoriasis [16]and some other diseases [17, 18]. …”

Section: Introductionmentioning

confidence: 99%

Incidental Control of Rosacea by Somatostatin

Piérard-Franchimont¹,

Quatresooz²,

Pierard³

2003

Dermatology

View full text Add to dashboard Cite

Background: The precise pathomechanism of rosacea remains elusive. The disease commonly requires long-term treatments using topical or oral therapies. Objective: This report presents incidental findings about the possible modulatory role of somatostatin in the outcome of rosacea. Method: Four patients presenting long-standing recalcitrant facial rosacea were treated with octreotide for diabetic retinopathy. Results: Rosacea improved rapidly and even cleared without any recurrence in 3 of the patients. Conclusion: The beneficial effect might be attributed to inhibitory actions on the sebaceous gland, the neovascularization and/or on the inflammatory process.

show abstract

Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology

Cited by 10 publications

References 0 publications

The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor.

The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor.

Relapsing Eruptive Psoriasis and Immunological Changes Triggered by Growth Hormone Therapy in a Growth Hormone-Deficient Girl

Incidental Control of Rosacea by Somatostatin

Contact Info

Product

Resources

About